RU2015127834A - Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина - Google Patents
Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина Download PDFInfo
- Publication number
- RU2015127834A RU2015127834A RU2015127834A RU2015127834A RU2015127834A RU 2015127834 A RU2015127834 A RU 2015127834A RU 2015127834 A RU2015127834 A RU 2015127834A RU 2015127834 A RU2015127834 A RU 2015127834A RU 2015127834 A RU2015127834 A RU 2015127834A
- Authority
- RU
- Russia
- Prior art keywords
- receptor antagonist
- glucagon receptor
- absorption inhibitor
- cholesterol absorption
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Claims (28)
1. Способ лечения диабета у млекопитающего субъекта, включающий введение указанному млекопитающему субъекту:
(a) антагониста рецептора глюкагона и
(b) ингибитора поглощения холестерина;
при этом у млекопитающего субъекта уровень в плазме ЛПНП холестерина составляет менее 130 мг/дл.
2. Способ уменьшения гипергликемии у млекопитающего субъекта, включающий введение указанному млекопитающему субъекту:
(a) антагониста рецептора глюкагона и
(b) ингибитора поглощения холестерина;
при этом у млекопитающего субъекта уровень в плазме ЛПНП холестерина составляет менее 130 мг/дл.
3. Способ по п. 1 или 2, отличающийся тем, что у субъекта уровень в плазме ЛПНП холестерина составляет менее 100 мг/дл.
4. Способ по п. 1 или 2, отличающийся тем, что соединение антагониста рецептора глюкагона и соединение ингибитора поглощения холестерина содержатся в одной лекарственной форме.
5. Способ по п. 4, отличающийся тем, что соединение антагониста рецептора глюкагона и соединение ингибитора поглощения холестерина содержатся в двухслойной таблетке.
6. Способ по п. 1 или 2, отличающийся тем, что соединение антагониста рецептора глюкагона и соединение ингибитора поглощения холестерина содержатся каждое в отдельной лекарственной форме для одновременного или последовательного введения.
7. Способ по п. 1 или 2, предназначенный для лечения диабета 2 типа.
8. Способ по п. 1 или 2, отличающийся тем, что соединение ингибитора поглощения холестерина представляет собой:
или его фармацевтически приемлемую соль.
9. Способ по п. 1 или 2, отличающийся тем, что соединение антагониста рецептора глюкагона представляет собой соединение, выбранное из следующей таблицы соединений:
или его фармацевтически приемлемую соль.
10. Комбинация, включающая:
(a) антагонист рецептора глюкагона и
(b) ингибитор поглощения холестерина,
предназначенная для лечения диабета у млекопитающего субъекта, имеющего уровень в плазме ЛПНП холестерина менее 130 мг/дл.
11. Применение комбинации, включающей:
(a) антагонист рецептора глюкагона и
(b) ингибитор поглощения холестерина,
для производства лекарственного средства, предназначенного для лечения диабета у млекопитающего субъекта, имеющего уровень в плазме ЛПНП холестерина менее 130 мг/дл.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261735304P | 2012-12-10 | 2012-12-10 | |
US61/735,304 | 2012-12-10 | ||
PCT/US2013/073780 WO2014093189A1 (en) | 2012-12-10 | 2013-12-09 | Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor |
Publications (1)
Publication Number | Publication Date |
---|---|
RU2015127834A true RU2015127834A (ru) | 2017-01-16 |
Family
ID=49877044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2015127834A RU2015127834A (ru) | 2012-12-10 | 2013-12-09 | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина |
Country Status (12)
Country | Link |
---|---|
US (2) | US20150320724A1 (ru) |
EP (1) | EP2928497B1 (ru) |
JP (1) | JP2016505555A (ru) |
KR (1) | KR20150092742A (ru) |
CN (1) | CN104822393A (ru) |
AR (1) | AR093851A1 (ru) |
AU (1) | AU2013359753A1 (ru) |
BR (1) | BR112015012447A2 (ru) |
CA (1) | CA2893074A1 (ru) |
RU (1) | RU2015127834A (ru) |
TW (1) | TW201427658A (ru) |
WO (1) | WO2014093189A1 (ru) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103933032B (zh) * | 2013-12-30 | 2019-08-23 | 北京赛林泰医药技术有限公司 | 作为抗癌药物的吡唑类衍生物的使用方法和用途 |
MX2017013807A (es) | 2015-04-30 | 2018-03-15 | Harvard College | Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos. |
CN107304180B (zh) * | 2016-04-22 | 2022-04-29 | 浙江海正药业股份有限公司 | 苯甲酰胺类衍生物、其制备方法及其在医药上的用途 |
BR112018076703A2 (pt) * | 2016-06-27 | 2019-04-02 | President And Fellows Of Harvard College | compostos úteis para tratar distúrbios metabólicos |
WO2018044967A1 (en) * | 2016-08-31 | 2018-03-08 | Virginia Commonwealth University | Local delivery of cholesterol-lowering drugs to treat and prevent bacterial vaginosis |
WO2018227200A1 (en) | 2017-06-09 | 2018-12-13 | President And Fellows Of Harvard College | Method to identify compounds useful to treat dysregulated lipogenesis, diabetes, and related disorders |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
US3630200A (en) | 1969-06-09 | 1971-12-28 | Alza Corp | Ocular insert |
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
HUT67341A (en) | 1991-07-23 | 1995-03-28 | Schering Corp | Substituted beta-lactam compounds useful as hypocholesterolemic agents, pharmaceutical compositions containing the same and process for the production thereof |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
US5756470A (en) | 1996-10-29 | 1998-05-26 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
US6207822B1 (en) | 1998-12-07 | 2001-03-27 | Schering Corporation | Process for the synthesis of azetidinones |
US6982251B2 (en) | 2000-12-20 | 2006-01-03 | Schering Corporation | Substituted 2-azetidinones useful as hypocholesterolemic agents |
US7071181B2 (en) | 2001-01-26 | 2006-07-04 | Schering Corporation | Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors |
EP1699453A4 (en) | 2003-12-19 | 2009-07-01 | Merck & Co Inc | CYCLIC GUANIDINES, COMPOSITIONS AND METHOD OF ADMINISTRATION CONTAINING SUCH COMPOUNDS |
WO2005121097A2 (en) * | 2004-06-04 | 2005-12-22 | Merck & Co., Inc. | Pyrazole derivatives, compositions containing such compounds and methods of use |
US7816557B2 (en) * | 2004-06-14 | 2010-10-19 | Eli Lilly And Company | Glucagon receptor antagonists, preparation and therapeutic uses |
DE102004028862A1 (de) | 2004-06-15 | 2005-12-29 | Merck Patent Gmbh | 3-Aminoindazole |
ATE449604T1 (de) | 2004-07-07 | 2009-12-15 | Merck & Co Inc | Pyrazolamid-derivate, diese verbindungen enthaltende zusammensetzungen und anwendungsverfahren |
ATE468853T1 (de) | 2004-07-22 | 2010-06-15 | Merck Sharp & Dohme | Substituierte pyrazole, derartige verbindungen enthaltende zusammensetzungen und verfahren zu ihrer verwendung |
CN101115735B (zh) | 2005-02-11 | 2013-01-09 | 伊莱利利公司 | 作为高血糖素受体拮抗剂的取代的噻吩衍生物、制备和治疗用途 |
WO2006102067A1 (en) | 2005-03-21 | 2006-09-28 | Merck & Co., Inc. | Substituted aryl and heteroaryl derivatives |
AU2006229904A1 (en) | 2005-03-30 | 2006-10-05 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US7709658B2 (en) | 2005-07-26 | 2010-05-04 | Merck Sharp & Dohme Corp. | Process for synthesizing a substituted pyrazole |
AR056574A1 (es) * | 2005-10-19 | 2007-10-10 | Merck & Co Inc | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso |
DE102005055726A1 (de) | 2005-11-23 | 2007-08-30 | Sanofi-Aventis Deutschland Gmbh | Hydroxy-substituierte Diphenylazetidinone, Verfahren zu deren Herstellung, diese Verbindungen enthaltende Arzneimittel und deren Verwendung |
TW200821284A (en) | 2006-10-03 | 2008-05-16 | Merck & Co Inc | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
KR20190126460A (ko) | 2007-02-09 | 2019-11-11 | 메타베이시스 테라퓨틱스, 인크. | 글루카곤 수용체의 길항제 |
AU2009246424A1 (en) | 2008-05-16 | 2009-11-19 | Schering Corporation | Glucagon receptor antagonists, compositions, and methods for their use |
EP2346830B1 (en) * | 2008-09-15 | 2015-05-13 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010036600A1 (en) * | 2008-09-24 | 2010-04-01 | Merck Sharp & Dohme Corp. | Pharmaceutical compositions of atorvastatin |
JP2012504630A (ja) * | 2008-10-03 | 2012-02-23 | シェーリング コーポレイション | グルカゴン受容体アンタゴニストとしてのスピロイミダゾロン誘導体 |
WO2010071750A1 (en) | 2008-12-19 | 2010-06-24 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds |
US20110281795A1 (en) | 2009-01-28 | 2011-11-17 | Songnian Lin | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US8324384B2 (en) | 2009-02-12 | 2012-12-04 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
US8809579B2 (en) | 2009-02-13 | 2014-08-19 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
WO2010098994A1 (en) | 2009-02-25 | 2010-09-02 | Merck Sharp & Dohme Corp. | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use |
JP2012188352A (ja) | 2009-07-13 | 2012-10-04 | Dainippon Sumitomo Pharma Co Ltd | 3−(4−置換アルキル−フェニル)−2−フランカルボン酸誘導体およびその薬学的に許容される塩 |
EP2552209A4 (en) * | 2010-03-26 | 2014-01-22 | Merck Sharp & Dohme | NOVEL IMIDAZOLONE SPIRO DERIVATIVES AS GLUCAGON RECEPTOR ANTAGONISTS, COMPOSITIONS, AND METHODS FOR USE THEREOF |
-
2013
- 2013-12-05 TW TW102144681A patent/TW201427658A/zh unknown
- 2013-12-06 AR ARP130104555A patent/AR093851A1/es unknown
- 2013-12-08 US US14/649,651 patent/US20150320724A1/en not_active Abandoned
- 2013-12-09 EP EP13811726.2A patent/EP2928497B1/en active Active
- 2013-12-09 CA CA2893074A patent/CA2893074A1/en not_active Abandoned
- 2013-12-09 BR BR112015012447A patent/BR112015012447A2/pt not_active IP Right Cessation
- 2013-12-09 WO PCT/US2013/073780 patent/WO2014093189A1/en active Application Filing
- 2013-12-09 KR KR1020157014968A patent/KR20150092742A/ko not_active Application Discontinuation
- 2013-12-09 RU RU2015127834A patent/RU2015127834A/ru not_active Application Discontinuation
- 2013-12-09 JP JP2015545903A patent/JP2016505555A/ja active Pending
- 2013-12-09 CN CN201380064457.2A patent/CN104822393A/zh active Pending
- 2013-12-09 AU AU2013359753A patent/AU2013359753A1/en not_active Abandoned
-
2017
- 2017-04-11 US US15/484,508 patent/US11077092B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
US11077092B2 (en) | 2021-08-03 |
US20170216250A1 (en) | 2017-08-03 |
US20150320724A1 (en) | 2015-11-12 |
AR093851A1 (es) | 2015-06-24 |
AU2013359753A1 (en) | 2015-05-14 |
KR20150092742A (ko) | 2015-08-13 |
TW201427658A (zh) | 2014-07-16 |
EP2928497B1 (en) | 2020-03-25 |
BR112015012447A2 (pt) | 2017-07-11 |
CA2893074A1 (en) | 2014-06-19 |
EP2928497A1 (en) | 2015-10-14 |
WO2014093189A1 (en) | 2014-06-19 |
JP2016505555A (ja) | 2016-02-25 |
CN104822393A (zh) | 2015-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2015127834A (ru) | Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина | |
RU2018108202A (ru) | Способы лечения синдрома леннокса-гасто с использованием фенфлурамина | |
JP2012193216A5 (ru) | ||
EA201270221A1 (ru) | Лечение болезни крона с применением лаквинимода | |
AR088458A1 (es) | Tratamiento de esclerosis multiple con la combinacion de laquinimod y fingolimod | |
JP2014528474A5 (ru) | ||
UA117103C2 (uk) | Сполука, яка має активність агоніста глюкагону | |
RU2017134443A (ru) | Способ лечения с применением традипитанта | |
MX2014005996A (es) | Anticuerpo anti - adrenomedulina (adm) o fragmento de anticuerpo anti - adm o un andamio no ig anti - adm para usarse en terapia. | |
EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
RU2013121788A (ru) | Ингибиторы репликации вич | |
EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
MY178654A (en) | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or an anti-adm non-ig protein scaffold for use in therapy | |
MX2012006744A (es) | Tiazolidinadionas reguladores de receptores activados por proliferador de peroxisoma (ppar) y combinaciones para el tratamiento de diabetes mellitus y otras enfermedades metabolicas. | |
RU2015134581A (ru) | Доноры нитроксила с улучшенным терапевтическим индексом | |
MX2013011174A (es) | Prevencion de hipoglucemia en pacientes con diabetes sacarina de tipo 2. | |
RU2014129508A (ru) | Новая комбинация | |
JP2012502103A5 (ru) | ||
FI2683245T4 (fi) | Menetelmiä ja koostumuksia masennuksen hoitamiseen syklobentsapriiniä käyttämällä | |
RU2015143475A (ru) | Продукт и способ лечения диареи | |
JP2015522077A5 (ru) | ||
JP2014513121A5 (ru) | ||
KR20190044667A (ko) | Fxr 작용제의 신규 요법 | |
EA201590474A1 (ru) | ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ НА ОСНОВЕ КОМПОЗИТНЫХ КАПСУЛ, ВКЛЮЧАЮЩИХ ИРБЕСАРТАН И ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ | |
RU2015139515A (ru) | Комбинированное лечение |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA93 | Acknowledgement of application withdrawn (no request for examination) |
Effective date: 20161213 |